Concepedia

David R. Fogelman

DR

89

Publications

6.5K

Citations

45

H-Index

1999

Active since

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

University College London

The University of Texas Health Science Center at Houston

Merck & Co., Inc., Rahway, NJ, USA (United States)

Duke Medical Center

David R. Fogelman is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and pathology.

ORCID

Top concepts

Publications per year

1999–2023

89

Publications

89

Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study

Luis A. Díaz, Kai‐Keen Shiu, Tae‐Won Kim et al. · The Lancet Oncology · 2022 · 818 citations · Full text

, , +9

Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point After Resection of Hepatic Colorectal Metastases

Dan G. Blazer, Yoji Kishi, Dipen M. Maru et al. · Journal of Clinical Oncology · 2008 · 593 citations

Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with <i>BRAF</i> V600E Mutation

David S. Hong, Van K. Morris, Badi El Osta et al. · Cancer Discovery · 2016 · 213 citations · Full text

Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues

Edward M. Wolin, Barbara Jarząb, Barbro Eriksson et al. · Drug Design Development and Therapy · 2015 · 204 citations · Full text

Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma

Giampaolo Perri, Laura Prakash, Wei Qiao et al. · JAMA Surgery · 2020 · 173 citations · Full text

Rows per page

1–5 of 89